Cancer Patients Challenge Bayer's $7.25B Roundup Settlement

Bayer's proposed $7.25 billion class action settlement of Roundup litigation is facing opposition from a group of lawyers representing nearly 20,000 plaintiffs who claim the deal will not be fair to cancer sufferers. The group filed a motion to intervene and a motion for an extension of the court's preliminary approval process, citing concerns about the settlement's terms.

The proposed settlement would pay users of the glyphosate-based weedkiller Roundup who have developed non-Hodgkin lymphoma between $10,000 and $165,000, depending on the severity of their illness. However, the intervening lawyers argue this range is too low and does not adequately compensate those affected by the cancer-causing herbicide.

{{IMAGE_PLACEHOLDER}}

The motion to intervene was filed in the St. Louis city circuit court in Missouri on February 24th, just days before the court was set to consider preliminary approval of the settlement. The intervening group, comprised of 14 law firms, is seeking more time to review the proposed deal and present their concerns to the court.

Bayer, the German chemical and pharmaceutical giant that acquired Monsanto in 2018, has faced thousands of lawsuits alleging that its Roundup weedkiller causes non-Hodgkin lymphoma. The company has already paid out over $11 billion to resolve previous Roundup-related cancer claims.

{{IMAGE_PLACEHOLDER}}

The intervening lawyers argue that the proposed settlement, if approved, would unfairly limit the compensation available to future Roundup cancer plaintiffs and potentially discourage them from seeking legal recourse. They contend that the settlement's terms are too favorable to Bayer and do not adequately address the long-term health impacts and financial burdens faced by those affected by the Roundup-related cancer.

This latest development in the ongoing Roundup litigation saga underscores the complex and contentious nature of the legal battles surrounding the widely-used herbicide. As Bayer continues to navigate these challenges, the outcome of the proposed settlement will have significant implications for both the company and the thousands of cancer patients seeking justice and fair compensation.

{{IMAGE_PLACEHOLDER}}